• 1
    LeWitt PA. Levodopa therapeutics for Parkinson's disease: new developments. Parkinsonism Relat Disord 2009;15(Suppl 1):S31-34.
  • 2
    Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1-8.
  • 3
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
  • 4
    Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012;27:106-112.
  • 5
    Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63:746-748.
  • 6
    Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014;29:229-237.
  • 7
    Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(7 Suppl 2):S18-S23.
  • 8
    Caccia C, Salvati P, Rossetti S, Anand R. Safinamide: beyond MAO-B inhibition. Parkinsonism Relat Disord 2007;13(Suppl 2):S99.
  • 9
    Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Current Opinion in Investigational Drugs 2007;8:570-579.
  • 10
    Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem 1998;41:579-590.
  • 11
    Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(7 Suppl 2):S24-29.
  • 12
    Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003;5:139-146.
  • 13
    Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 2013;19:508-514.
  • 14
    Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
  • 15
    Barone P, Fernandez H, Ferreira JJ, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study) [Abstract]. 65th AAN Annual Meeting, American Academy of Neurology, 16-23 March 2013, San Diego, California, USA. Neurology 2013;80(Meeting Abstracts 1):P01.061.
  • 16
    Schapira AH, Fox S, Hauser RA, et al. Safinamide add on to L-dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson's Disease (PD) and Motor fluctuations (SETTLE) [Abstract]. 65th AAN Annual Meeting, American Academy of Neurology, 16-23 March 2013, San Diego, California, USA. Neurology 2013;80(Meeting Abstracts 1):P01.062.
  • 17
    Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011;26:587-598.